Increasing incidence is fuelling the Hepatocellular Carcinoma Market




The most common form of primary liver cancer, Hepatocellular Carcinoma (HCC) is a malignant tumour of hepatocytes.
Increasing Hepatocellular Carcinoma (HCC) Incidence
Hepatocellular Carcinoma incidence is growing worldwide because of the dissemination of Hepatitis B and C virus infection making it the fifth most common cause of cancer.
 Hepatocellular cell carcinoma is found to be more common in males as compared to females. 
Moreover, 70%–90% of HCC patients have a previous history of chronic liver disease and cirrhosis.
This indicates their chances of being diagnosed with chronic infection with hepatitis B virus (HBV), hepatitis C virus (HCV), alcoholic liver disease, and non-alcoholic steatohepatitis (NASH).
According to DelveInsight, a healthcare business consulting firm, the total HCC incident cases in G8 countries estimated to be around 4,58,170 in 2016.  
On the other hand, the total Diagnosed Advanced Hepatocellular Carcinoma cases in G8 countries around 1, 60,565 cases and the numbers are expected to increase in the coming years.
Moreover, DelveInsight estimates that the total HCC patients in G8 countries on first- and second-line therapies were 39,224 and 14,215, respectively.
Increasing Hepatocellular Carcinoma therapy market 
Opdivo developed by Bristol-Myers Squibb is approved only in the US and Stivarga, again a Bayer’s therapy got FDA recommendation in 2017 itself. Both of the treatments have created a positive impact on the Hepatocellular Carcinoma market size.
Other Hepatocellular Carcinoma therapies include Miripla [Miriplatin, Dainippon Sumitomo Pharma], and Lenvima which got approved only in Japan. 
Booming Hepatocellular Carcinoma market 
Hepatocellular Carcinoma Market analysis demonstrates that the HCC Market size was about USD 723.4 million in 2016 in G8 countries.
DelveInsight estimates that the United States had the highest Hepatocellular Carcinoma market share in 2016, as compared to EU5 (Germany, France, Italy, Spain & UK) Japan and China. Among EU5, Italy has the highest Hepatocellular market, while the UK had the lowest HCC market.
At present, the Hepatocellular Carcinoma therapeutic market size is mainly accounted for by the protein Kinase inhibitor, i.e., Nexavar (Sorafenib), a product of Bayer.
Hepatocellular Carcinoma Emerging Drugs Analysis
The dynamics of Hepatocellular Carcinoma market is anticipated to change in the coming years owing to the expected launch of therapies.
There are presently three emerging therapies focused on the treatment of HCC- Ramucirumab (Eli Lilly; 2nd Line of Therapy), Cabozantinib (Exelixis; 2nd Line of Therapy), and Lenvima (Eisai Pharmaceuticals & Merck; 1st Line of therapy).


Comments

Post a Comment

Popular posts from this blog

Cyclin-dependent kinase

Image
Cyclin-dependent kinase overview Cyclin-dependent kinases (CDKs) belong to a protein serine/threonine kinases whose activity depends on association with a noncatalytic regulatory subunit called a cyclin. Cyclin-dependent kinases inhibitors are vital for progression through the cell cycle and proliferation. The genes that encode CDKs were initially identified in screens for conditional mutants of Saccharomyces cerevisiae which reversibly arrested at characteristic points in the cell cycle upon transfer to the restrictive conditions. Cyclins were initially named for their periodic accumulation and degradation (cycling) through the early cell cycles of fertilized sea urchin eggs. This research identified a ubiquitous cell cycle engine responsible for coordinating cell growth, DNA replication, and mitosis in the orderly fashion required to ensure the viability of progeny cells. How Do Cyclin-dependent kinases regulate Cell Cycle? All eukaryotes have a various cyclins,
Read more

Tenosynovial Giant Cell Tumors (TSGCTs) Market Research Report 2030 | Tenosynovial Giant Cell Tumors (TSGCTs) Market

Image
Tenosynovial Giant Cell Tumors   are a type of neoplasm that affects synovial-lined tendon sheaths, synovial joints, and surrounding soft tissue. Locally aggressive benign tissue lesions are defined by synovial lining inflammation in joints and tendons. Overexpression of the colony-stimulating factor 1 receptor is thought to cause these tumors to form. Giant cell tumors of the tendon sheath (GCTTS), pigmented villonodular tumors (PVNTS), extra-articular pigmented villonodular tumors of the tendon sheath, and localized or focal nodular synovitis are all terms used to describe TSGCTs. Tenosynovial Giant Cell Tumors Causes Translocation is an alteration to a chromosome that causes Tenosynovial Giant Cell Tumors. A chromosome segment breaks off and moves around. The cause of these translocations is unknown. The genetic code for making proteins is stored on chromosomes. A protein termed colony-stimulating factor 1 is produced in excess due to the translocation (CSF1). This protein attracts
Read more

Smoking Cessation Market Research Report 2030 | Smoking Cessation Market

Image
Smoking Cessation   is a process of discontinuing tobacco smoking. Cigarette smoking is the leading cause of chronic obstructive pulmonary disease, and quitting smoking is the most effective way to slow down the progression of the disease. Tobacco use can potentially lead to tobacco or nicotine addiction, as well as significant health consequences, according to the CDC. It has the potential to significantly lower the risk of smoking-related diseases. Nicotine is addictive, but no effective medications or behavioral therapies are available to help people overcome it. Counseling, nicotine replacement, and bupropion have all been shown to aid in smoking cessation in several studies. Smoking Cessation Sign and Symptoms The most significant barrier to quitting smoking is nicotine addiction. Smokers who try to stop often experience cravings for cigarettes, mood swings, insomnia, constipation, increased hunger, anxiety, and other nicotine withdrawal symptoms. Tobacco quitting lowers the chanc
Read more